前列腺床术后消融性放疗(POPART)后毒性与肿瘤学结局的预测因素
本研究分析前列腺癌根治术后生化复发患者接受前列腺床SBRT(32.5 Gy/5次)的毒性预测因素、患者报告结局及生化复发情况。100例患者中位随访19.6个月,急性≥G2泌尿毒性为0,5%出现G2胃肠道毒性;晚期G2泌尿毒性6.4%,G3放射性膀胱炎1.1%。较大的CTV和较高的基线肠道评分预测急性G2胃肠道毒性,急性尿失禁MCID预测晚期G2泌尿毒性。ISUP分级是生化复发的显著预测因素。
要点
- 前列腺床SBRT 32.5 Gy/5次耐受性良好,急性≥G2泌尿毒性为0。
- 较大的CTV和较高的基线肠道评分预测急性G2胃肠道毒性。
- 急性尿失禁MCID预测晚期G2泌尿毒性,ISUP分级预测生化复发。
核心结论
- 前列腺床SBRT是可行且耐受性良好的治疗方案,生化控制结局充分。
- 急性症状可预示晚期副作用,ISUP分级是生化复发的显著预测因素。
研究设计与样本
- 前瞻性分析100例组织学确诊前列腺癌、PSA 0.1-2.0 ng/mL且PSMA PET无转移的患者。
- 患者接受前列腺床SBRT 32.5 Gy分5次隔日照射,中位随访19.6个月(范围3.5-42.4)。
- 毒性采用CTCAE v5.0评估,生活质量采用ICIQ-SF、IIEF 5和EPIC-CP问卷在基线和随访时评估,MCID定义为变化>0.5 SD。
- 统计分析包括ANOVA、logistic回归和Cox回归模型(p<0.05为显著),Kaplan-Meier分析估计生化无复发生存期(BRFS)。
主要发现
- 急性毒性:无≥G2泌尿事件,5%出现G2胃肠道毒性。
- 晚期毒性:6.4%出现G2泌尿事件,1.1%出现G3放射性膀胱炎,1.1%出现G2胃肠道毒性。
- 较大的CTV和较高的基线肠道评分是急性G2胃肠道毒性的预测因素。
- 急性尿失禁MCID是晚期G2泌尿毒性的预测因素。
- 较高的膀胱壁和阴茎球剂量与更差的泌尿和性功能结局相关。
关键数值与推荐
- 纳入标准:组织学确诊前列腺癌、PSA 0.1-2.0 ng/mL、PSMA PET无转移。
- 放疗方案:前列腺床SBRT 32.5 Gy分5次,隔日照射。
- MCID定义为问卷评分变化>0.5 SD。
- 统计学显著性设定为p<0.05。
临床怎么用
- 前列腺床SBRT可作为根治术后生化复发患者的 salvage 治疗选择,需关注CTV大小和基线肠道症状以预测急性胃肠道毒性。
- 急性尿失禁MCID的出现提示需警惕晚期泌尿毒性,膀胱壁和阴茎球剂量应予以控制以保护泌尿和性功能。
- ISUP分级可用于风险分层,高级别肿瘤患者BRFS率更低,需加强随访。
局限性
- 中位随访仅19.6个月,长期结局尚未明确。
- 需要长期随访和对比试验以进一步确立SBRT在此 setting 中的地位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salvage radiotherapy to the prostate bed (PB) is the standard treatment for biochemical recurrence after radical prostatectomy. Emerging evidence supports hypofractionation, including Stereotactic Body Radiation Therapy (SBRT), in this setting. Predictive factors for toxicity, patient-reported outcomes (PROs) and biochemical recurrence following salvage SBRT to the PB are analyzed in this study. MATERIALS AND METHODS: Patients with histologically confirmed prostate cancer, PSA 0.1-2.0 ng/mL, and no metastases on PSMA PET, received postoperative SBRT to the prostate bed (32.5 Gy in five fractions, every other day). Toxicity was assessed using CTCAE v5.0, while QoL was measured via ICIQ-SF, IIEF 5, and EPIC-CP questionnaires at baseline and follow-up, with MCID defined as changes > 0.5 SD. PSA levels were also measured to assess oncological outcomes. Statistical analyses included ANOVA, logistic and Cox regression models (p < 0.05 significant). Kaplan-Meier analysis estimated biochemical recurrence-free survival (BRFS). RESULTS: Between April 2021 and September 2023, 100 patients (median age: 71) were treated with a median follow-up of 19.6 months (range: 3.5-42.4). Acute toxicity analysis showed no ≥ G2 GU events and 5 % G2 GI toxicity. Late toxicity included 6.4 % G2 GU events, 1.1 % G3 radiation cystitis, and 1.1 % G2 GI toxicity. Larger CTV and higher baseline bowel scores were predictors of acute G2 GI toxicity, while acute urinary incontinence MCID predicted late G2 GU toxicity. Higher bladder wall and penile bulb doses were associated with worse urinary and sexual outcomes. Biochemical recurrence occurred in 18 patients, with a median time of 10 months. ISUP grade was a significant predictor of recurrence, with lower BRFS rates in higher-grade tumors. CONCLUSIONS: SBRT to the PB is a feasible and well-tolerated approach with adequate biochemical control outcomes. Acute symptoms anticipated late side effects. Long-term follow-up and comparative trials are needed to strengthen the role of SBRT in this setting.
引用
- Ferrario F, Franzese C, Vukcaj S, et al. Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrence. Radiother Oncol. 2025. PMID: 40759283. doi:10.1016/j.radonc.2025.111072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。